BC055107 Inhibitors
BC055107, a protein with emerging significance, is associated with transcriptional regulation and cellular processes governing cell growth and differentiation. While detailed information regarding its function is under investigation, BC055107's involvement in key signaling pathways underscores its importance in cellular physiology. BC055107 inhibition is potentially achieved through diverse compounds targeting critical signaling pathways. Notably, EGFR inhibitors such as Gefitinib, AG1478, Lapatinib, and Erlotinib selectively impact EGFR signaling, influencing BC055107 expression and function indirectly. These inhibitors may modulate cellular processes related to transcriptional regulation and cell growth, shedding light on the intricate network of BC055107 interactions.
In addition to EGFR inhibitors, U0126 and PD0325901 disrupt the MAPK/ERK pathway, potentially affecting BC055107 in the context of cellular growth and differentiation. SB202190, a p38 MAPK inhibitor, may influence BC055107 expression and function through the p38 MAPK pathway, highlighting the interconnectedness of BC055107 with diverse signaling cascades. Furthermore, mTOR inhibitors such as AZD8055, PI3K inhibitors like LY294002, and IGF-1R inhibitor AG-1024 potentially impact BC055107 indirectly by disrupting the mTOR, PI3K/Akt, and IGF-1R pathways, respectively. These inhibitors may alter BC055107 expression and function, influencing cellular processes associated with transcriptional regulation and cell growth. In conclusion, BC055107 inhibitors serve as valuable tools for unraveling the functional significance of this protein in cellular processes. The potential diverse mechanisms of inhibition, targeting multiple signaling pathways, offer a nuanced perspective on the interconnected regulatory networks that converge on BC055107. Continued research into the precise functions of BC055107 and the effects of these inhibitors will undoubtedly contribute to a deeper understanding of the intricate molecular pathways governing cellular growth and differentiation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
EGFR inhibitor. Gefitinib targets the EGFR pathway, potentially influencing BC055107 indirectly. This interference may impact BC055107 expression and function, altering cellular processes associated with transcriptional regulation and cell growth. | ||||||
Tyrphostin AG 1478 | 175178-82-2 | sc-200613 sc-200613A | 5 mg 25 mg | $94.00 $413.00 | 16 | |
EGFR inhibitor. Tyrphostin AG 1478 selectively inhibits EGFR, potentially impacting BC055107 indirectly. This interference may alter BC055107 expression and function, modulating cellular processes related to transcriptional regulation and cell growth. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Dual EGFR/HER2 inhibitor. Lapatinib inhibits both EGFR and HER2, potentially influencing BC055107 indirectly. This interference may impact BC055107 expression and function, affecting cellular processes associated with transcriptional regulation and cell growth. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
EGFR inhibitor. Erlotinib selectively targets EGFR, potentially modulating BC055107 indirectly. This interference may alter BC055107 expression and function, influencing cellular processes related to transcriptional regulation and cell growth. | ||||||
PD 169316 | 152121-53-4 | sc-204168 sc-204168A sc-204168B sc-204168C | 1 mg 5 mg 10 mg 25 mg | $86.00 $153.00 $275.00 $452.00 | 3 | |
p38 MAPK inhibitor. SB202190 influences the p38 MAPK pathway, potentially modulating BC055107 expression and function in specific cellular contexts. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
JAK2 inhibitor. Tyrphostin B42 selectively inhibits JAK2, potentially influencing BC055107 indirectly. This interference may impact BC055107 expression and function, altering cellular processes related to transcriptional regulation and cell growth. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
mTOR inhibitor. AZD8055 disrupts the mTOR pathway, which crosstalks with BC055107 signaling. This interference may influence BC055107 expression and function, impacting transcriptional regulation and cellular processes related to cell growth and differentiation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor targeting the PI3K/Akt pathway. LY294002 disrupts the PI3K/Akt pathway, which crosstalks with BC055107 signaling. This interference may influence BC055107 expression and function, altering downstream cellular processes associated with transcriptional regulation and cellular differentiation. | ||||||
AG 1024 | 65678-07-1 | sc-205907 | 1 mg | $105.00 | 22 | |
IGF-1R inhibitor. AG-1024 selectively inhibits IGF-1R, potentially influencing BC055107 indirectly. This interference may impact BC055107 expression and function, modulating cellular processes related to transcriptional regulation and cell growth. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
MEK inhibitor targeting the MAPK/ERK pathway. Trametinib disrupts the MAPK/ERK pathway, potentially affecting BC055107 expression and function in the context of cellular growth and differentiation. | ||||||